{"doi":"10.1016/j.omto.2023.05.007","title":"Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers","abstract":"Adoptive cell therapy (ACT) utilizing γδ T cells is becoming a promising option for the treatment of cancer, because it offers an off-the-shelf allogeneic product that is safe, potent, and clinically effective. Approaches to engineer or enhance immune-competent cells for ACT, like expression of chimeric antigen receptors (CARs) or combination treatments with bispecific T cell engagers, have improved the specificity and cytotoxic potential of ACTs and have shown great promise in preclinical and clinical settings. Here, we test whether electroporation of γδ T cells with CAR or secreted bispecific T cell engager (sBite) mRNA is an effective approach to improve the cytotoxicity of γδ T cells. Using a CD19-specific CAR, approximately 60% of γδ T cells are modified after mRNA electroporation and these cells show potent anticancer activity in vitro and in vivo against two CD19-positive cancer cell lines. In addition, expression and secretion of a CD19 sBite enhances γδ T cell cytotoxicity, both in vitro and in vivo , and promotes killing of target cells by modified and unmodified γδ T cells. Taken together, we show that transient transfection of γδ T cells with CAR or sBite mRNA by electroporation can be an effective treatment platform as a cancer therapeutic.","journal":"Molecular Therapy — Oncolytics","year":2023,"id":336266,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9492,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":432519,"name":"Brian G. Petrich","orcid":"0000-0003-1915-3261","position":1,"is_corresponding":false},{"id":1066695,"name":"Bing Yu","orcid":"0000-0002-7039-3706","position":2,"is_corresponding":false},{"id":733686,"name":"Kristopher A. Knight","orcid":"0000-0002-7948-0072","position":3,"is_corresponding":false},{"id":1067156,"name":"Harrison C. Brown","orcid":null,"position":4,"is_corresponding":false},{"id":492435,"name":"Sunil S. Raikar","orcid":"0000-0003-2903-9542","position":5,"is_corresponding":false},{"id":380170,"name":"Christopher B. Doering","orcid":"0000-0002-5662-0060","position":6,"is_corresponding":false},{"id":380171,"name":"H. Trent Spencer","orcid":"0000-0001-8062-2202","position":7,"is_corresponding":false},{"id":469158,"name":"Scott A. Becker","orcid":"0000-0003-0194-4874","position":0,"is_corresponding":true}],"reference_count":63,"raw_metadata":null,"created_at":"2026-07-19T01:10:17.243221Z","pmid":"37387794","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}